Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

durvulamab

- PMLiVE

AstraZeneca shares late-stage results for Airsupra in mild asthma patients

More than ten million asthma exacerbations occur in the US every year

- PMLiVE

Merck’s Welireg granted FDA approval to treat rare tumour types PPGL

Up to 2,000 new cases of pheochromocytoma or paraganglioma are diagnosed in the US every year

Physician talking to elderly patient

Motivations that matter: Understanding clinical trial participation to create better research

Understanding why people join clinical trials is essential to improving recruitment and designing better research. Explores the diverse motivations driving participation — from altruism and hope for better health to...

Cuttsy + Cuttsy

- PMLiVE

FDA approves Fujirebio’s Lumipulse as first Alzheimer’s disease blood test

The device offers a less invasive option compared to current PET scans and CSF tests

- PMLiVE

AbbVie’s Emrelis granted FDA accelerated approval to treat advanced lung cancer

An estimated 226,650 people will be diagnosed with lung cancer in the US this year

- PMLiVE

AstraZeneca announces positive phase 3 results for Imfinzi in high-risk bladder cancer

Around half of NMIBC patients are classed as being high-risk for disease progression or recurrence

- PMLiVE

FDA approves Verastem Oncology’s combination therapy for rare ovarian cancer type

Approximately 6,000 to 8,000 women in the US are living with low-grade serous ovarian cancer

- PMLiVE

AstraZeneca/Daiichi Sankyo share positive phase 3 results for Enhertu in early breast cancer

Around one in three patients with early-stage breast cancer are considered high risk

- PMLiVE

FDA announces rapid rollout of AI system to accelerate drug review process

The move follows the completion of a new AI-assisted scientific review pilot

The (clinical) trials and tribulations of gene therapy – why meaningful patient engagement strategies matter

By Sarah Mohamad and Lauren Coleman-Bennett

Amiculum

- PMLiVE

AstraZeneca’s Calquence approved by EC for first-line mantle cell lymphoma use

The drug is now the only BTK inhibitor to be approved in the EU for first-line MCL

- PMLiVE

Bristol Myers Squibb’s injectable Opdivo formulation granted MHRA for solid tumours

The new formulation reduces administration time from 30-to-60 minutes to three-to-five minutes

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links